Most researchers looking for CJC-1295 in Jaqué soon discover that local retail options are nearly impossible to find. The practical advantage of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers access to better quality signals than any physical store could provide. Separating properly characterised CJC-1295 from the rest of the market requires three things: an HPLC chromatogram confirming ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Jaqué researchers need to know about purchasing, testing, and working with CJC-1295 for scientific research use.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Jaqué comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade CJC-1295
The first step for any Jaqué researcher sourcing CJC-1295 is identifying 2-3 vendors with documented positive community reputations — commercial rankings reflect SEO budgets rather than product quality. When reviewing a CJC-1295 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are below the threshold for research use. For Jaqué researchers evaluating vendors with limited track records: a test quantity before committing to research volumes before committing to research quantities is what experienced peptide researchers consistently do. For Jaqué researchers making a first CJC-1295 purchase: apply these quality criteria before ordering, begin with a small order, and confirm the COA batch number matches your received product before use.
Order CJC-1295 — ships to Jaqué
COA-verified · International tracking · Research grade
All use of CJC-1295 in Jaqué or anywhere is research use only — this compound is not approved for clinical human use, and all handling should comply with standard research safety practices. Proper handling of CJC-1295 requires strict sterile technique during reconstitution — alcohol-swabbed septum, fresh needles, clean working environment — and cold chain maintenance from receipt through use. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger dangerous immune responses at very low concentrations, and no pricing advantage justifies skipping this verification. PubMed and bioRxiv represent the most comprehensive research databases for CJC-1295 research; focus on peer-reviewed publications with documented compound quality over case reports or anecdotal evidence.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
